Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation

Inclusion Criteria: * Age 18 years of older. * The latest PCI with DES implantation before 12 months (stents must be one or more sirolimus-eluting stents). * Angiographically confirmed major epicardial vessels (\>=2.5mm in diameter) without significant stenosis or restenosis (\>=50%). * Geographically accessible and willing to come in for required study visits. * Signed informed consent. Exclusion Criteria: * The patient has a known hypersensitivity or contraindication to aspirin and clopidogrel. * Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema) at the time of enrollment and within 12 months. * EF\<35% within 12 months. * Severe cardiac valves disease, or idiopathic cardiomyopathy such as dilated cardiomyopathy, hypotrophic cardiomyopathy. Other severe system diseases. * Previous ACS within 12 months. * Previous stroke or transient ischemia attack within 12 months. * Previous myocardial infarction and clinical-driven target vessel revascularization within 12 months. * Current enrollment in another clinical trial. * Suspected pregnancy. * Big bleeding events within 12 months. * Planned surgical procedure. * Previous other type DES implantation or BMS implantation history. * Extra-cardiac stent implantation history. * Current or planned dialysis. * The patient has a known hypersensitivity or contraindication to statins. * Current or planned high dose and long-term glucocorticoid treatment. * that is expected to limit survival to less than 1 years.